Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-01T21:16:18.575Z Has data issue: false hasContentIssue false

Authors' reply

Published online by Cambridge University Press:  02 January 2018

Magali Haas
Affiliation:
Johnson & Johnson Pharmaceutical Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium. Email: mhaas8@its.jnj.com
Marielle Eerdekens
Affiliation:
Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen
Pharmaceutica NV
Affiliation:
Beerse, Belgium
Stuart Kushner
Affiliation:
Johnson & Johnson Pharmaceutical Research & Development, LLC, New Jersey, USA
Julia Singer
Affiliation:
Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen
Ilse Augustyns
Affiliation:
Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen
Pharmaceutica NV
Affiliation:
(deceased)
Vivek Kusumakar
Affiliation:
(deceased)
Jorge Quiroz
Affiliation:
Johnson & Johnson Pharmaceutical Research & Development, LLC, New Jersey, USA
Gahan Pandina
Affiliation:
Johnson & Johnson Pharmaceutical Research & Development, LLC, New Jersey, USA
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2009 

References

1 Aman, MG, De Smedt, G, Derivan, A, Findling, RL, Group RDBS. Double-blind, placebo-controlled study of risperidone in the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337–46.CrossRefGoogle Scholar
2 Reyes, M, Buitelaar, J, Toren, P, Augustyns, I, Eerdekens, M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163: 402–10.CrossRefGoogle ScholarPubMed
3 Stroup, TS, Alves, WM, Hamer, RM, Lieberman, JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Rev 2006; 5: 133–46.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.